Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Strasse 10, 13125 Berlin, Germany.
Institute of Chemistry, Technische Universität Berlin, Strasse des 17. Juni 135, 10623 Berlin, Germany.
Int J Mol Sci. 2022 Jan 11;23(2):763. doi: 10.3390/ijms23020763.
The cAMP-dependent aquaporin-2 (AQP2) redistribution from intracellular vesicles into the plasma membrane of renal collecting duct principal cells induces water reabsorption and fine-tunes body water homeostasis. However, the mechanisms controlling the localization of AQP2 are not understood in detail. Using immortalized mouse medullary collecting duct (MCD4) and primary rat inner medullary collecting duct (IMCD) cells as model systems, we here discovered a key regulatory role of Aurora kinase A (AURKA) in the control of AQP2. The AURKA-selective inhibitor Aurora-A inhibitor I and novel derivatives as well as a structurally different inhibitor, Alisertib, prevented the cAMP-induced redistribution of AQP2. Aurora-A inhibitor I led to a depolymerization of actin stress fibers, which serve as tracks for the translocation of AQP2-bearing vesicles to the plasma membrane. The phosphorylation of cofilin-1 (CFL1) inactivates the actin-depolymerizing function of CFL1. Aurora-A inhibitor I decreased the CFL1 phosphorylation, accounting for the removal of the actin stress fibers and the inhibition of the redistribution of AQP2. Surprisingly, Alisertib caused an increase in actin stress fibers and did not affect CFL1 phosphorylation, indicating that AURKA exerts its control over AQP2 through different mechanisms. An involvement of AURKA and CFL1 in the control of the localization of AQP2 was hitherto unknown.
环磷酸腺苷依赖性水通道蛋白-2(AQP2)从细胞内囊泡重新分布到肾集合管主细胞的质膜中,诱导水的重吸收,并精细地调节体内水的动态平衡。然而,控制 AQP2 定位的机制尚未被详细了解。本研究使用永生化的小鼠髓袢集合管(MCD4)和原代大鼠内髓集合管(IMCD)细胞作为模型系统,发现 Aurora 激酶 A(AURKA)在控制 AQP2 中具有关键的调节作用。AURKA 选择性抑制剂 Aurora-A 抑制剂 I 和新型衍生物以及结构不同的抑制剂 Alisertib,可防止 cAMP 诱导的 AQP2 重新分布。Aurora-A 抑制剂 I 导致肌动蛋白应力纤维解聚,肌动蛋白应力纤维作为 AQP2 囊泡向质膜易位的轨道。原肌球蛋白-1(CFL1)的磷酸化使 CFL1 的解聚活性失活。Aurora-A 抑制剂 I 降低了 CFL1 的磷酸化,导致肌动蛋白应力纤维的去除和 AQP2 重新分布的抑制。令人惊讶的是,Alisertib 导致肌动蛋白应力纤维增加,并不影响 CFL1 的磷酸化,表明 AURKA 通过不同的机制对 AQP2 发挥其控制作用。AURKA 和 CFL1 参与控制 AQP2 的定位在此前是未知的。